Dr. Daniel Wallace Appointed to Lupus Therapeutics Board
New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors. Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […]
Welcoming Daniel J. Wallace, MD to Lupus Therapeutics
The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors. A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate […]
Board of Directors
Angelica Perez Finds a Simple Way to Make a Huge Difference – You Can Too!
December, 2023 Participating in the LRA’s Lupus Landmark Study was a “no-brainer” says Angelica Perez, a 37-year-old woman living with lupus since she was nine. “I had been taking part in clinical trials for years to potentially improve my own care while helping to advance new treatments overall.” A patient of renowned Los Angeles lupus […]
Lupus Therapeutics, filial de Lupus Research Alliance, desarrolla un estudio que se enfoca en los pacientes con lupus y la COVID-19
7 de abril de 2020 Nueva York, NY, 7 de abril de 2020 – Lupus Therapeutics, la filial de ensayos clínicos de Lupus Research Alliance (LRA), anunció hoy que está iniciando un estudio clínico para evaluar el posible beneficio de la hidroxicloroquina u otras terapias para el lupus con el fin de evitar o […]
Lupus Therapeutics, Affiliate of Lupus Research Alliance, Developing a Study Focused on Lupus Patients and COVID-19
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus. The study […]
MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community
March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […]
Lupus and COVID-19:What You Need to Know Webcast on Video
April 3, 2020 The Lupus Research Alliance (LRA) hosted a live webcast April 2, 2020 on COVID-19 for people with lupus that you won’t want to miss – so click here to view the full video recording. The webast addressed the most frequently asked questions doctors are hearing from people with lupus, put the hydroxychloroquine […]
DECLARACIÓN DEL 26 DE MARZO: La Alianza para la investigación de Lupus pone en perspectiva la escasez de Plaquenil (hidroxicloroquina) para la comunidad con lupus
26 de marzo de 2020 La Alianza para la investigación de Lupus (LRA), la principal organización de investigación del mundo dedicada a la investigación del lupus, continúa observando rápidamente los cambios en relación con la COVID-19 y está controlando de cerca las políticas y acciones del gobierno federal, las agencias de atención médica, las organizaciones […]
New Study Shows Active Epstein-Barr Virus Increases Chance for Lupus in At-Risk People
August 13, 2019 New research results showed that active Epstein-Barr virus increases the risk for lupus among relatives of people who already have lupus. Epstein-Barr virus is one of the most common human viruses. After the first infection, the virus becomes inactive in your body and can reactivate at any time. Scientists have known that […]